【24h】

Large-scale preparation of thrombin from human plasma.

机译:从人血浆中大规模制备凝血酶。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Thrombin was prepared from human blood plasma (batch size 1200 L). First, prothrombin was isolated by the following separation techniques: cryoprecipitation, ion-exchange chromatography (diethyl aminoethyl, DEAE-IEX), heparin affinity chromatography, a second DEAE-IEX step, and immobilized metal-affinity chromatography (IMAC). Prothrombin was then activated to thrombin, which was purified by hydrophobic interaction chromatography (HIC) and concentrated by ultrafiltration. This process is cost-effective because a waste fraction can be used from one of the steps (heparin affinity chromatography) in the commercial production of plasma-derived Factor IX (FIX). The final thrombin preparation had a purity of approximately 75% (specific activity approximately 2400 IU/mg protein), which is sufficient for its intended purpose in a fibrin glue. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Factor X (FX) activity analysis, and analytical HIC were also used to characterize the thrombin. Three substantially different techniques were used to reduce any viral activity, namely: solvent/detergent (S/D) treatment, pasteurization, and virus filtration (nanofiltration). The manufacturing process presented here would be suitable for large-scale production of thrombin with a high degree of virus safety.
机译:凝血酶由人血浆(批号1200 L)制备。首先,通过以下分离技术分离凝血酶原:冷冻沉淀,离子交换色谱法(二乙基氨基乙基,DEAE-IEX),肝素亲和色谱法,第二步DEAE-IEX步骤和固定化金属亲和色谱法(IMAC)。然后将凝血酶原活化为凝血酶,然后通过疏水相互作用色谱(HIC)进行纯化,并通过超滤进行浓缩。该方法具有成本效益,因为可以在血浆衍生的因子IX(FIX)的商业化生产中使用步骤(肝素亲和色谱法)中的一种废物。最终的凝血酶制剂的纯度约为75%(比活性约为2400 IU / mg蛋白),足以满足其在纤维蛋白胶中的预期目的。十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE),X因子(FX)活性分析和分析性HIC也用于表征凝血酶。三种基本不同的技术用于降低任何病毒活性,即:溶剂/洗涤剂(S / D)处理,巴氏灭菌和病毒过滤(纳米过滤)。这里介绍的制造工艺将适合大规模生产具有高度病毒安全性的凝血酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号